Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection

Table 3 PET majority, AD and mCERAD_SOT assessment by disease category

Disease category	Number	Percent	PETmaj abnormal	# With coincident AD^a	# mCERAD_SOT abnormal
Alzheimer's Disease^a	66	(62%)	62	66	64
Lewy Body Disease^b	29	(27%)	23	16	22
Cerebral Amyloid Angiopathy^c	27	(25%)	23	24	25
Vascular^d	21	(20%)	14	14	16
Arteriosclerosis^e	13	(12%)	9	9	11
Infarct	7	(7%)	3	2	3
Normal	6	(6%)	0	0	0
Ageing Changes	3	(3%)	0	0	0
TDP43 immunopositive^f	3	(3%)	0	0	2
Tangle predominant dementia	2	(2%)	0	0	0
Progressive Supranuclear Palsy	2	(2%)	0	0	0
Atherosclerosis	2	(2%)	1	2	2
Frontotemporal Dementia	1	(1%)	0	0	0
Metastatic carcinoma	1	(1%)	1	1	1
Hydrocephalus	1	(1%)	1	1	1
Multiple system atrophy	1	(1%)	1	0	1
Neurofibrillary degeneration	1	(1%)	0	0	1
Parkinson's Disease	1	(1%)	0	0	0

AD Alzheimer’s disease, mCERAD _SOT standard of truth by modified Consortium to Establish a Registry for Alzheimer’s Disease criteria, N Number of subjects, PETmaj majority read of positron emission tomography images, SOT standard of truth
All neuropathology diagnoses made blind to clinical data
^aIncludes intermediate or high likelihood by National Institute of Ageing-Reagan Institute criteria irrespective of dementia status
^bDiagnosed as dementia with Lewy bodies blinded to clinical data
^cDoes not include focal cerebral amyloid angiopathy
^dIncludes: multifocal infarcts, microinfarcts, cerebral vascular disease, vascular brain injury and vascular dementia
^eincludes arteriosclerosis and arteriolosclerosis
^fTDP43 immunopositivity was recorded at the site neuropathology laboratories, not as part of the diagnoses for the GE studies. This analysis was not performed on all subjects

ISSN: 2051-5960